modelDorzolamide
Extends from Pharmacolibrary.Drugs.ATC.S.S01EC03.
Information
| name: | Dorzolamide | |
| ATC code: | S01EC03 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 1.5 | mL/min/kg |
| other parameters in model implementation | ||
Dorzolamide is a carbonic anhydrase inhibitor primarily used as an ophthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is approved and widely used in clinical practice today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers (ophthalmic administration). Dorzolamide accumulates in erythrocytes due to high affinity for carbonic anhydrase II. Minimal systemic exposure due to local ocular administration.
References
Schmitz, K, et al., & Behrens-Baumann, W (1999). Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans. Investigative ophthalmology & visual science 40(7) 1621–1624. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10359348
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)